Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Multiple Myeloma 29Lymphoma 23Colorectal Neoplasms 18Breast Neoplasms 18Pancreatic Neoplasms 17Prostatic Neoplasms 16Myelodysplastic Syndromes 16Lymphoma, Large B-Cell, Diffuse 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Triple Negative Breast Neoplasms 13Melanoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Sarcoma 10Neuroblastoma 9Neoplasms 9Glioma 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, T-Cell 8Leukemia, Biphenotypic, Acute 8Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Myeloproliferative Disorders 7Lymphoma, Non-Hodgkin 7

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Biopsy × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡